MedTrace Logo

Pegylated Interferon Lambda Treatment for COVID-19

NCT04343976 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 14

Last updated 2022-07-21

Study results available
· View outcomes & findings →

Summary

Prospective randomized trial to assess the antiviral efficacy of Pegylated Interferon Lambda (180 mcg SC injection) vs.placebo in up to 20 subjects with COVID-19 infection.

Conditions

Interventions

DRUG

Pegylated interferon lambda

180 mcg subcutaneous injection of pegylated interferon lambda

Sponsors & Collaborators

  • Eiger BioPharmaceuticals

    collaborator INDUSTRY

  • Raymond Chung

    lead OTHER

Principal Investigators

  • Raymond Chung, MD · Massachusetts General Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-06-22
Primary Completion
2021-07-30
Completion
2021-07-30
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04343976 on ClinicalTrials.gov